ArticleFrontiers in oncology2025
CD302 regulates the malignant phenotypes of lung adenocarcinoma as a tumor suppressor gene.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: CD302 encodes a transmembrane glycoprotein involved in immune regulation via cell-extracellular matrix interactions. Its role in lung adenocarcinoma (LUAD) remains unexplored. This study investigates CD302's expression, clinical relevance, and functional mechanisms in LUAD. Methods: Using public databases and bioinformatics, CD302 expression and clinical significance were analyzed. Validation was performed in 52 paired NSCLC samples from the Department of Thoracic Surgery at the Affiliated Hospital of Zunyi Medical University using RT-qPCR and clinical correlation analysis. Results: Database analysis revealed that CD302 exhibited low expression in lung adenocarcinoma tissues, with its expression levels being negatively correlated with T stage, N stage, and TNM stage. Patients with high CD302 expression demonstrated significantly higher overall survival (OS) and progression-free survival (PFS). Both univariate and multivariate Cox regression analyses identified CD302 expression as an independent prognostic factor for LUAD patients. A nomogram was constructed to predict 1-, 3-, and 5-year survival rates, and calibration curve analyses confirmed the model's robust predictive capability. The area under the ROC curve (AUC) of 0.912 further suggests that CD302 holds substantial diagnostic potential. Analysis of clinical NSCLC samples validated the low expression of CD302 in lung adenocarcinoma, with expression levels showing a negative correlation with tumor diameter (correlation coefficient = -0.5358). Moreover, using the human lung adenocarcinoma cell lines A549 and PC-9, a CD302 overexpression model was established. Subsequent CCK-8, colony formation, wound healing, and transwell invasion assays demonstrated that CD302 overexpression inhibits the proliferation, migration, and invasion of NSCLC cells. Conclusion: CD302 is expressed at low levels in lung adenocarcinoma tissues, and its expression is negatively correlated with tumor diameter, serving as an independent risk factor for poor prognosis in lung adenocarcinoma patients. Overexpression of CD302 inhibits the proliferation, migration, and invasion of A549 and PC-9 cells. Therefore, CD302 holds potential as a diagnostic and prognostic biomarker for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.